about
Investigations on the synthesis and pharmacological properties of N-substituted derivatives of 4-alkoxy-6-methyl-1H-pyrrolo[3,4-c]pyridine-1,3(2H)-dionesA Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced ObesityH3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice.Ergotamine and nicergoline - facts and myths.Synthesis and adrenolytic activity of new propanolamines.Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-(2-(2-methoxy phenoxy)ethylamino)propan-2-ol analogs and its enantiomers. Part 2.Tissue distribution of gold nanoparticles after single intravenous administration in mice.Are anti-inflammatory properties of lipoic acid associated with the formation of hydrogen sulfide?Bioactivation of nitroglycerin to nitric oxide (NO) and S-nitrosothiols in the rat liver and evaluation of the coexisting hypotensive effect.Synthesis and evaluation of in vivo activity of diphenylhydantoin basic derivatives.The effect of NaCl on the level of reduced sulfur compounds in rat liver. Implications for blood pressure increase.The role of lipoic acid in prevention of nitroglycerin tolerance.Synthesis and evaluation of some xanthone derivatives for anti-arrhythmic, hypotensive properties and their affinity for adrenergic receptors.Antiarrhythmic activity of some xanthone derivatives with β1-adrenoceptor affinities in rats.Pyrrolidin-2-one derivatives may reduce body weight in rats with diet-induced obesity.Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action.Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist.Novel multi-target azinesulfonamides of cyclic amine derivatives as potential antipsychotics with pro-social and pro-cognitive effects.Arylsulfonamide derivatives of (aryloxy)ethyl pyrrolidines and piperidines as α1-adrenergic receptor antagonist with uro-selective activity.Antiarrhythmic and α-Adrenoceptor Antagonistic Properties of Novel Arylpiperazine Derivatives of Pyrrolidin-2-one.Antiarrhythmic activity in occlusion-reperfusion model of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino} propan-2-ol and its enantiomers.Synthesis and biological evaluation of N-arylpiperazine derivatives of 4,4-dimethylisoquinoline-1,3(2H,4H)-dione as potential antiplatelet agents.Synthesis and Analgesic Activity of Annelated Xanthine Derivatives in Experimental Models in Rodents.The nitric oxide/soluble cyclic guanylase/cyclic guanosine monophosphate pathway is involved in the cardiovascular effects of a novel α1- and β-adrenoceptor antagonistSynthesis and Pharmacological Evaluation of Novel Silodosin-Based Arylsulfonamide Derivatives as α/α-Adrenergic Receptor Antagonist with Potential Uroselective ProfileThe influence of the route of administration of gold nanoparticles on their tissue distribution and basic biochemical parameters: In vivo studiesEvaluation of anticonvulsant activity of novel pyrrolidin-2-one derivativesApplication of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasmaAntiarrhythmic properties of phenylpiperazine derivatives of phenytoin with α₁-adrenoceptor affinitiesα-Adrenoceptor antagonistic and hypotensive properties of novel arylpiperazine derivatives of pyrrolidin-2-oneSynthesis and Pharmacological Activity of a New Series of 1-(1H-Indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol AnalogsDesign, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agentsDesign, synthesis, anticonvulsant, and antiarrhythmic properties of novel N-Mannich base and amide derivatives of β-tetralinohydantoinAlpha lipoic acid protects the heart against myocardial post ischemia-reperfusion arrhythmias via KATP channel activation in isolated rat heartsIsolation of 1-(3',4'-Dihydroxyphenyl)-3-(2″,4″,6″-trihydroxyphenyl)-propan-2-ol from Grape Seed Extract and Evaluation of its Antioxidant and Antispasmodic PotentialKSK19 - Novel histamine H3 receptor ligand reduces body weight in diet induced obese miceStructural modifications and in vitro pharmacological evaluation of 4-pyridyl-piperazine derivatives as an active and selective histamine H3 receptor ligandsAnti-Alzheimer's multitarget-directed ligands with serotonin 5-HT6 antagonist, butyrylcholinesterase inhibitory, and antioxidant activityCharacteristics of metabolic stability and the cell permeability of 2-pyrimidinyl-piperazinyl-alkyl derivatives of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione with antidepressant- and anxiolytic-like activitiesAnti-inflammatory activity of lipoic acid in mice peritonitis model
P50
Q28213292-21F4DBDF-0AF8-4539-B20B-FD4C3AE2D66EQ28550518-8251C892-F30F-41B8-A6DB-F4FE87A11C94Q37273493-08DE212C-0CF2-4067-9C8B-891116A120A8Q38364945-D513BA7A-9A6A-40BA-B989-F1CB0CFC5D24Q42958817-5A6B4D9B-D826-45EB-8375-0DCD7D1CBD7FQ43300596-02317DFB-C2FA-480C-8A7E-D8787B49F801Q43534122-E390AAC0-5F73-4CEC-9652-D3473C37190FQ44349321-51127412-9D1D-4FE2-95EC-D0C98D98C57CQ45018836-1D339B05-1F3F-489C-BCB7-BCEF2D64B00CQ45168301-4082411F-0CAA-404E-B871-FAD3D4FD819FQ46323666-27F112B2-2027-4A0B-A145-F9FAD4048C41Q46490928-DF579891-3A57-493F-A240-26F5DFAC7256Q46778801-436F49DB-6845-456F-A734-3788B367D02CQ46903664-736C8F43-7A14-48EF-A220-B76635C401A4Q47324338-E33AF9F7-70AF-4FB4-950C-D0B79ADDE672Q48069023-BBDC045A-7E5D-470A-B8BD-26DA57010450Q50129258-449FA66D-8C1C-4518-8E22-FADFC51A239CQ50174817-4ABB6916-05BB-413B-A0A5-52B8F1DF89F0Q51473592-CFBF2277-3176-4C90-B592-9BCAB8DE536BQ51740483-FD23FF49-0B43-4E69-983B-5B5EC8E63CA3Q52149069-E1E19C31-0584-4F79-8519-80FB5BDF2CB5Q52684757-0E515496-8B7F-4FBF-BE44-4A64A5E5A6DBQ53393422-54DC44CD-FEED-4D28-9298-C163CD85AA12Q57111935-28D402CF-D153-4BA3-99CB-14282534E7F6Q58691700-A036F9DA-9BEF-419D-B3A5-743794202A21Q60473659-AF40A143-36EA-4CE8-B523-E7C926F44214Q60473668-DAEF6BA7-D62E-4726-A7DA-45356D7AE25AQ80213638-408C8B7F-26C0-4E2E-A2CC-2FE7F13861C5Q83550593-4E27AB3F-9DA9-4575-ABBD-07EECEF664A0Q86999804-01916FAF-4299-40E0-ABE5-73C9ACA081F3Q87243955-A85E7DDC-7A8D-44A4-B0E7-F328CA3AF677Q87483458-D4C6555D-EFF9-48E8-923D-F77C580922BEQ87772396-ABDFD2EA-B4BD-4A82-A9A4-11A98629C226Q88032187-C5C792E9-087C-41B5-A5A7-F3487F94AADDQ91658839-7178262A-591D-432E-9A22-BBBA2ECAC0A6Q91798309-D193BEED-7530-46B6-BF5B-668878FBE8BAQ92289198-33BFED69-C8BF-4805-9339-3E533B439BD9Q92513743-ACFA74BD-D68B-430C-BBF8-3E46839351FFQ93031823-EFA2FE74-0B05-4EB8-9DE4-4F9FF7FEAF2EQ95444005-586A7ED9-83A5-4A25-8840-4923215E375F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Marek Bednarski
@en
Marek Bednarski
@nl
type
label
Marek Bednarski
@en
Marek Bednarski
@nl
prefLabel
Marek Bednarski
@en
Marek Bednarski
@nl
P31
P496
0000-0002-4639-9913